Pictures

A handout photograph distributed by Syria's national news agency SANA on May 22,2013, show detained men, blindfolded and handcuffed, described by SANA as "terrorists fighters", a term commonly used to describe rebels fighting to topple President Bashar al-Assad, in Qusair, near Homs. SANA/Handout via Reuters

Reuters Photojournalism

Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography.  See more 

Photo

Devastated by Tornado

A huge tornado tears through an Oklahoma City suburb.  Slideshow 

Photo

The drone wars

The frontlines of America's covert drone program.  Slideshow 

Sponsored Links

Pfizer kidney cancer drug fails as initial treatment

Related Topics

The entrance of Pfizer World headquaters in New York City, August 31, 2003. REUTERS/Jeff Christensen

The entrance of Pfizer World headquaters in New York City, August 31, 2003.

Credit: Reuters/Jeff Christensen

Wed Oct 17, 2012 6:22am EDT

(Reuters) - Pfizer Inc said its kidney cancer drug did not meet the main goal of showing a statistically significant improvement in survival in a late-stage trial without the cancer getting worse.

The trial was testing the drug Inlyta in patients who have received no prior treatments and compared its effects with another kidney cancer drug, sorafenib. Inlyta is already approved to treat kidney cancer that has not responded to prior therapy.

Sorafenib is marketed as Nexavar by Onyx Pharmaceuticals Inc and Germany's Bayer AG. (Reporting by Esha Dey in Bangalore; Editing by Sreejiraj Eluvangal)
Health
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.